Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal...
19 insider purchases on record · latest filing 2025-12-29.
Insiders have also filed 31 sale transactions at MNPR.